About KATRD Q&A Journal Search Archive Contact us Sitemap Register Login Admin
ISSN: 1738-3536(Print)
                      ISSN: 2005-6184(Online)
Archive Journal Search Q&A About KATRD
Home > Archive
A Case of Typhlitis Developed after Chemotherapy with Irinotecan and Cisplatin in a Patient with Small Cell Lung Carcinoma
Eun Hye Ji, M.D., Young Min Kim, M.D., Soo Jeong Kim, M.D., Soo Jeong Yeom, M.D., Sung Eun Ha, M.D., Hyeon Hui Kang, M.D., Ji Young Kang, M.D., Sang Haak Lee, M.D., Hwa Sik Moon, M.D
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea
Tuberculosis and Respiratory Diseases; 2012 November; 73 (5): 288-291


Conclusion : Typhlitis is a necrotizing colitis that usually occurs in neutropenic patients and develops most often in patients with hematologic malignancies such as leukemia and lymphoma. Typhlitis may proceed to bowel perforation, peritonitis and sepsis, which requires immediate treatment. Irinotecan is a semisynthetic analogue of the natural alkaloid camptothecin which prevents DNA from unwinding by inhibition of topoisomerase I. It is mainly used in colon cancer and small cell lung carcinoma (SCLC), of which the most common adverse effects are gastrointestinal toxicities. To the best of our knowledge, no case of typhlitis after chemotherapy with a standard dose of irinotecan in a solid tumor has been reported in the literature. We, herein, report the first case of typhlitis developed after chemotherapy combining irinotecan and cisplatin in a patient with SCLC.

Keywords : Typhlitis; Irinotecan; Small Cell Lung Carcinoma

Reference :
1. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
2. Bleiberg H, Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer 1996; 32A Suppl 3:S18-23.
3. Gorschlüter M, Mey U, Strehl J, Ziske C, Schepke M, Schmidt-Wolf IG, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 2005;75:1-13.
4. Keidan RD, Fanning J, Gatenby RA, Weese JL. Recurrent typhlitis: a disease resulting from aggressive chemotherapy. Dis Colon Rectum 1989;32:206-9.
5. Oh YS, Yoo JH, Kim YR, Hahn CW, Park CW, Shin WS, et al. Four cases of typhlitis in patients with acute leukemia. Korean J Med 1995;49:550-5.
6. Cartoni C, Dragoni F, Micozzi A, Pescarmona E, Mecarocci S, Chirletti P, et al. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol 2001;19:756-61.
7. Kim YB, Lee SJ, Lee YH, Lee YK, Sin SK, Kim JS, et al. A case of typhlitis developed after anticancer chemotherapy in a patient with solid tumor. Korean J Med 2002;62:657-60.
8. Tiseo M, Gelsomino F, Bartolotti M, Barili MP, Ardizzoni A. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report. Lung Cancer 2009;65:251-3.
9. Rodriguez-Galindo C, Crews KR, Stewart CF, Furman W, Panetta JC, Daw NC, et al. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol 2006;57:15-24.
10. Hahn KK, Wolff JJ, Kolesar JM. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm 2006;63: 2211-7.
11. Shamberger RC, Weinstein HJ, Delorey MJ, Levey RH. The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 1986;57:603-9.

about archive search Instruction to Author Q&A Registration Contact Us Sitemap Member Admin KATRD